In mouse mammary tumors treated with paclitaxel, aTim-3 mAbs act in Tim-3+ tumor-infiltrating cDCs to promote CXCL9-mediated recruitment of CD8+ T cells in a galectin-9–dependent fashion (25). Here, HAVCR2 is linked to neoplasm.